Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
One in two women with advanced ovarian cancer has an HRD-positive tumor
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
First and only PARP inhibitor to improve invasive disease-free survival in patients
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Subscribe To Our Newsletter & Stay Updated
